Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

* TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed t...

2026-04-30 05:00 6741

Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-28 07:44 6400

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:50 6666

Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-15 06:35 7706

Telix Refinances Convertible Bonds

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals L...

2026-04-14 16:32 7238

Telix and Regeneron Announce Strategic Radiopharma Collaboration

* Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical ther...

2026-04-13 06:57 6318

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-10 06:50 7155

Telix Strengthens Board with Additional Director Appointments

MELBOURNE, Australia and INDIANAPOLIS, April 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-04-09 06:58 5378

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-07 06:57 7429

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-04-02 06:59 5976

Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited...

2026-03-16 05:26 5902

ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives

* Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March ...

2026-03-10 06:34 5836

Investor Education Webinar

The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, Mar...

2026-03-02 06:56 4891

FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-20 07:27 13832

Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-02-18 05:54 8903

Telix Full Year Results 2025 Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (...

2026-02-04 05:38 9186

First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients

MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ...

2026-01-29 07:43 8446

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Li...

2026-01-20 15:16 10907

Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-20 06:15 6783

First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited ...

2026-01-17 03:21 5818